AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases, particularly those related to cellular metabolism. The company specializes in creating precision medicines for hemolytic anemias, with its lead product candidate, mitapivat, undergoing late-stage clinical trials for thalassemia and sickle cell disease. Agios also develops investigational therapies, including AG-946, and maintains a research engine to advance multiple novel treatments in preclinical development. The company engages closely with patients and collaborators to inform its research and development efforts.